Sale!

FMF First Trimester Screen Test

510 د.إ

-11%

The FMF (Fetal Medicine Foundation) First Trimester Screen Test is a comprehensive prenatal screening test conducted during the first trimester of pregnancy. This test is designed to assess the risk of certain chromosomal abnormalities in the fetus, including Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13). The screening involves a combination of maternal blood tests and ultrasound measurements, specifically the nuchal translucency measurement, to evaluate the risk levels for these conditions.

Performed at DNA Labs UAE, a reputable facility known for its advanced diagnostic services, the FMF First Trimester Screen Test offers expecting parents an early insight into the genetic health of their fetus. The test is priced at 510 AED, making it an accessible option for many families seeking peace of mind during pregnancy. DNA Labs UAE employs state-of-the-art technology and follows stringent protocols to ensure accurate and reliable results, providing crucial information for the ongoing management of the pregnancy.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

FMF FIRST TRIMESTER SCREEN Test

Test Cost: AED 510.0

Test Name: FMF FIRST TRIMESTER SCREEN Test

Components: Price: 510.0 AED

Sample Condition: 2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen. Provide maternal Date of Birth (dd/mm/yy), LMP, USG report between 11-13 weeks gestation including CRL, NT & Nasal Bone, number of fetuses; Diabetic status, body weight; IVF, Smoking & Previous h/o Trisomy 21. Duly filled Patient demographic details in Maternal Serum Screen Requisition Form (Form 11) is mandatory. Valid between 9-13 weeks gestation (Ideal 10-13 weeks).

Report Delivery: Sample Tue / Thu / Sat by 9 am; Report Same day

Method: ECLIA

Test type: Prenatal Diagnosis

Doctor: Gynecologist

Test Department: IMMUNOASSAY

Pre Test Information: Duly filled Patient demographic details in Maternal Serum Screen Requisition Form (Form 11) is mandatory. Valid between 9-13 weeks gestation (Ideal 10-13 weeks).

Test Details

The FMF (Fetal Medicine Foundation) First Trimester Screen is a prenatal screening test that combines an ultrasound examination and blood tests to assess the risk of certain chromosomal abnormalities in the fetus. It is typically performed between 11 to 14 weeks of pregnancy.

The test involves two components:

  1. Ultrasound Examination: This involves measuring the nuchal translucency (NT), which is the fluid-filled space at the back of the baby’s neck. Increased NT thickness is associated with an increased risk of certain chromosomal abnormalities, such as Down syndrome. The ultrasound also evaluates other fetal structures and confirms the gestational age.
  2. Blood Tests: Two blood tests are performed as part of the First Trimester Screen. The first is a maternal blood test that measures the levels of pregnancy-associated plasma protein-A (PAPP-A), and the second is a blood test that measures the levels of human chorionic gonadotropin (hCG). Deviations from normal levels of these hormones can indicate an increased risk of chromosomal abnormalities.

The results of the ultrasound and blood tests are combined with the mother’s age and gestational age to calculate the overall risk of chromosomal abnormalities. This risk is presented as a ratio, such as 1 in 500, indicating the likelihood of the fetus having a chromosomal abnormality.

It is important to note that the FMF First Trimester Screen is a screening test, not a diagnostic test. If the screening results indicate a high risk, further diagnostic tests, such as chorionic villus sampling (CVS) or amniocentesis, may be recommended to confirm the presence of a chromosomal abnormality.

It is advisable to discuss the benefits, limitations, and potential risks of the FMF First Trimester Screen with a healthcare provider to make an informed decision about whether to undergo the test.

Test Name FMF FIRST TRIMESTER SCREEN Test
Components
Price 510.0 AED
Sample Condition 2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen. Provide maternal Date of Birth (dd\/mm\/yy), LMP, USG report between 11-13 weeks gestation including CRL, NT & Nasal Bone, number of fetuses; Diabetic status, body weight; IVF, Smoking & Previous h\/o Trisomy 21. Duly filled Patient demographic details in Maternal Serum Screen Requisition Form (Form 11) is mandatory. Valid between 9-13 weeks gestation (Ideal 10-13 weeks).
Report Delivery SampleTue / Thu / Sat by 9 am; Report Same day
Method ECLIA
Test type Prenatal Diagnosis
Doctor Gynecologist
Test Department: IMMUNOASSAY
Pre Test Information Duly filled Patient demographic details in Maternal Serum Screen Requisition Form (Form 11) is mandatory. Valid between 9-13 weeks gestation (Ideal 10-13 weeks).
Test Details

The FMF (Fetal Medicine Foundation) First Trimester Screen is a prenatal screening test that combines an ultrasound examination and blood tests to assess the risk of certain chromosomal abnormalities in the fetus. It is typically performed between 11 to 14 weeks of pregnancy.

The test involves two components:

1. Ultrasound Examination: This involves measuring the nuchal translucency (NT), which is the fluid-filled space at the back of the baby’s neck. Increased NT thickness is associated with an increased risk of certain chromosomal abnormalities, such as Down syndrome. The ultrasound also evaluates other fetal structures and confirms the gestational age.

2. Blood Tests: Two blood tests are performed as part of the First Trimester Screen. The first is a maternal blood test that measures the levels of pregnancy-associated plasma protein-A (PAPP-A), and the second is a blood test that measures the levels of human chorionic gonadotropin (hCG). Deviations from normal levels of these hormones can indicate an increased risk of chromosomal abnormalities.

The results of the ultrasound and blood tests are combined with the mother’s age and gestational age to calculate the overall risk of chromosomal abnormalities. This risk is presented as a ratio, such as 1 in 500, indicating the likelihood of the fetus having a chromosomal abnormality.

It is important to note that the FMF First Trimester Screen is a screening test, not a diagnostic test. If the screening results indicate a high risk, further diagnostic tests, such as chorionic villus sampling (CVS) or amniocentesis, may be recommended to confirm the presence of a chromosomal abnormality.

It is advisable to discuss the benefits, limitations, and potential risks of the FMF First Trimester Screen with a healthcare provider to make an informed decision about whether to undergo the test.